282 related articles for article (PubMed ID: 31234673)
1. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Hwang G; Johri A; Ng S; Craig T
Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
[TBL] [Abstract][Full Text] [Related]
2. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
3. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
5. Lanadelumab to treat hereditary angioedema.
Wedi B
Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
Wang Y; Marier JF; Kassir N; Chang C; Martin P
Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
[TBL] [Abstract][Full Text] [Related]
7. Lanadelumab: First Global Approval.
Syed YY
Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
[TBL] [Abstract][Full Text] [Related]
8. Lanadelumab for the treatment of hereditary angioedema.
Wu MA
Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
[No Abstract] [Full Text] [Related]
9. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
Bova M; Valerieva A; Wu MA; Senter R; Perego F
Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331
[TBL] [Abstract][Full Text] [Related]
10. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
[TBL] [Abstract][Full Text] [Related]
11. The bradykinin-forming cascade and its role in hereditary angioedema.
Kaplan AP; Joseph K
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
[TBL] [Abstract][Full Text] [Related]
12. Biological therapy in hereditary angioedema: transformation of a rare disease.
Longhurst H; Farkas H
Expert Opin Biol Ther; 2020 May; 20(5):493-501. PubMed ID: 31994957
[No Abstract] [Full Text] [Related]
13. Bradykinin-mediated diseases.
Kaplan AP
Chem Immunol Allergy; 2014; 100():140-7. PubMed ID: 24925394
[TBL] [Abstract][Full Text] [Related]
14. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
[TBL] [Abstract][Full Text] [Related]
15. Lanadelumab: A Review in Hereditary Angioedema.
Syed YY
Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
[TBL] [Abstract][Full Text] [Related]
16. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
Stehlin F; Ribi C
Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
Zuraw BL; Maurer M; Sexton DJ; Cicardi M
Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
[TBL] [Abstract][Full Text] [Related]
18. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
[TBL] [Abstract][Full Text] [Related]
19. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
20. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]